4-phenoxyindan-1-one | 62803-52-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-phenoxyindan-1-one
• 英文别名: 4-phenoxy-2,3-dihydroinden-1-one；4-Phenoxy-2,3-dihydro-1H-inden-1-one
• CAS: 62803-52-5
• 化学式: C₁₅H₁₂O₂
• 分子量: 224.259
• InChiKey: XUAFOJPRPWYVAM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-phenoxyindan-1-one 在 sodium tetrahydroborate 、 氯化亚砜 作用下， 以 甲醇 为溶剂， 生成 1-Chlor-4-phenoxyindan
  参考文献：
  名称：

  Aono,T. et al., Chemical and pharmaceutical bulletin, 1978, vol. 26, p. 2475 - 2482

  摘要：

  DOI：
• 作为产物：
  描述：

  4-羟基-1-茚酮 、 二苯基碘酰氯 在 sodium hydroxide 作用下， 生成 4-phenoxyindan-1-one
  参考文献：
  名称：

  Aono,T. et al., Chemical and pharmaceutical bulletin, 1978, vol. 26, p. 2475 - 2482

  摘要：

  DOI：

文献信息

• NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE
  申请人：Okano Akihiro

  公开号：US20120157459A1

  公开（公告）日：2012-06-21

  [Problem] To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of solving the problem] A compound of Formula (I): (where n is 0 to 2; p is 0 to 4; j is 0 to 3; k is 0 to 2; a ring A is an aryl group which is optionally substituted with L or a heterocyclic group which is optionally substituted with L; a ring B is a benzene ring, a pyridine ring, or a pyrimidine ring; X is O, S, —NR 7 —; and R 1 to R 7 are specific groups), a salt of the compound, or a solvate of the salt or the compound.

  提供一个以新型化合物作为活性成分的GPR40激活剂，该化合物具有GPR40激动剂作用，该化合物的盐，该盐或化合物的溶剂合物，或者类似物，尤其是胰岛素分泌促进剂以及对糖尿病、肥胖症或其他疾病的预防及/或治疗剂。[解决该问题的方法] 公式(I)的化合物：（其中n为0至2；p为0至4；j为0至3；k为0至2；环A是一个芳基团，可选择性被L取代或是一个杂环团，可选择性被L取代；环B是一个苯环、一个吡啶环或一个嘧啶环；X是O，S，—NR7—；R1至R7是特定基团），该化合物的盐，或该盐或化合物的溶剂合物。
• Studies on 5-Lipoxygenase Inhibitors. I. Synthesis and 5-Lipoxygenase-Inhibitory Activity of Novel Hydroxamic Acid Derivatives.
  作者：Takumi YATABE、Yoshio KAWAI、Teruo OKU、Hirokazu TANAKA

  DOI：10.1248/cpb.46.966

  日期：——

  A series of novel hydroxamates has been prepared and tested for inhibitory activity towards rat polymorphonuclear leukocyte (PMN) 5-lipoxygenase (5-LO) in vitro and towards neutrophil migration in the rat air pouch model of inflammation in vivo. Many 3, 4-dihydronaphthyl compounds were potent inhibitors of 5-LO, and several compounds were potent inhibitors of neutrophil migration. The most potent 3, 4-dihydronaphthyl compound, N-[[(3, 4-dihydro-5-phenoxy)-2-naphthyl]methyl]-N-hydroxy-N'-ethylurea (FR122788, 18) had an IC50 of 25 nM in the 5-LO assay, and strongly reduced neutrophil migration in the rat air pouch model at 1 mg/kg (p.o.). FR122788 also had an ameliorating effect in a rat hepatiatis model induced by D-galactosamine, with an ED<50> values of 14.6 mg/kg (p.o.) for glutamate oxaloacetate transaminase (GOT) and 16.8 mg/kg (p.o.) for glutamate pyruvate transaminase (GPT).

  已制备了一系列新型异羟肟酸盐，并测试了其对体外大鼠多形核白细胞 (PMN) 5-脂氧合酶 (5-LO) 的抑制活性以及体内大鼠气袋炎症模型中对中性粒细胞迁移的抑制活性。许多3, 4-二氢萘基化合物是5-LO的有效抑制剂，并且一些化合物是中性粒细胞迁移的有效抑制剂。最有效的 3, 4-二氢萘基化合物 N-[[(3, 4-二氢-5-苯氧基)-2-萘基]甲基]-N-羟基-N'-乙基脲 (FR122788, 18) 的 IC50 为5-LO 测定中浓度为 25 nM，1 mg/kg（口服）可显着降低大鼠气囊模型中的中性粒细胞迁移。 FR122788还在D-半乳糖胺诱导的大鼠肝炎模型中具有改善作用，谷氨酸草酰乙酸转氨酶(GOT)的ED 50 值为14.6mg/kg(口服)，谷氨酸丙酮酸的ED 50 值为16.8mg/kg(口服)。转氨酶（GPT）。
• Aminophenylpropanoic Acid Derivative
  申请人：Yasuma Tsuneo

  公开号：US20080269220A1

  公开（公告）日：2008-10-30

  A compound represented by the formula (1): wherein each symbol is as defined in the specification, and a salt thereof and a prodrug thereof unexpectedly have superior GPR40 receptor agonist activity, superior in the properties as a pharmaceutical product such as stability and the like, and can be a safe and useful pharmaceutical agent as a drug for the prophylaxis or treatment of GPR40 receptor related pathology or diseases such as diabetes and the like.

  化合物的化学式为（1）：其中每个符号如规范所定义，其盐和前药意外地具有更优越的GPR40受体激动剂活性，在药品产品的稳定性等方面具有优越性，并且可以作为安全有效的药物用于预防或治疗GPR40受体相关的病理或疾病，例如糖尿病等。
• 3-hydroxy-5-arylisothiazole derivative
  申请人：Okano Akihiro

  公开号：US08476287B2

  公开（公告）日：2013-07-02

  [Problem] To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of solving the problem] A compound of Formula (I): (where n is 0 to 2; p is 0 to 4; j is 0 to 3; k is 0 to 2; a ring A is an aryl group which is optionally substituted with L or a heterocyclic group which is optionally substituted with L; a ring B is a benzene ring, a pyridine ring, or a pyrimidine ring; X is O, S, —NR7—; and R1 to R7 are specific groups), a salt of the compound, or a solvate of the salt or the compound.

  [问题]提供一种GPR40激活剂，其活性成分为具有GPR40激动剂作用的新化合物、该化合物的盐、盐或化合物的溶剂化物等，特别是胰岛素促分泌剂和预防和/或治疗糖尿病、肥胖症或其他疾病的药物。[解决问题的方法]化合物(I)的公式：（其中n为0至2；p为0至4；j为0至3；k为0至2；环A为芳基基团，可选地取代L或杂环基团，可选地取代L；环B为苯环、吡啶环或嘧啶环；X为O、S、-NR7-；R1至R7为特定的基团），该化合物的盐或盐或化合物的溶剂化物。
• AMINOPHENYLPROPANOIC ACID DERIVATIVE
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1726580A1

  公开（公告）日：2006-11-29

  A compound represented by the formula (1): wherein each symbol is as defined in the specification, and a salt thereof and a prodrug thereof unexpectedly have superior GPR40 receptor agonist activity, superior in the properties as a pharmaceutical product such as stability and the like, and can be a safe and useful pharmaceutical agent as a drug for the prophylaxis or treatment of GPR40 receptor related pathology or diseases such as diabetes and the like.

  式 (1) 所代表的化合物： 其中各符号如说明书中所定义，其盐及其原药意外地具有优异的 GPR40 受体激动剂活性、优异的稳定性等药剂特性，可作为预防或治疗 GPR40 受体相关病理或疾病（如糖尿病等）的安全有用的药剂。